China Metallurgical Group Corporation (MCC) reported a 24.5% year-over-year decrease in new contract value for the first half of 2026, totaling 413.64 billion yuan. The second quarter alone saw a 34.6% decline in new contract value. Separately, Fosun Pharma announced that its subsidiary received approval from China's National Medical Products Administration to conduct clinical trials for a Parkinson's disease treatment. AI
RANK_REASON The cluster contains financial results for a large state-owned enterprise and a regulatory approval for a drug trial, neither of which rise to the level of significant industry news.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
